In June 2026, the U.S. Food and Drug Administration approved a change to the Drug Facts label for OTC Alli (orlistat 60 mg) warning about rare kidney stones and kidney injury. Orlistat can increase intestinal absorption of oxalate under certain circumstances, contributing to high urinary oxalate, calcium oxalate stones or, rarely, oxalate-related kidney damage. This page explains what the FDA update says, who should seek clinical advice before using the medicine and which symptoms call for prompt attention. It is not a test for kidney disease.
The June 10, 2026 communication asks people with any prior kidney disease or kidney stones to consult a healthcare professional before taking Alli. It also names back or groin pain, painful urination, blood in urine, swollen feet or legs and decreased urination as warning symptoms. People who develop these symptoms while using Alli should stop taking it and seek medical evaluation. Severe or rapidly worsening symptoms warrant urgent medical care; do not try to diagnose or treat a possible kidney injury from a web article.
This focused review differs from the broader orlistat side-effects overview, which covers common digestive reactions and other rare events. The contraindications guide addresses conditions that exclude or complicate use. OrliLab is an independent educational and affiliate-supported publication, not a pharmacy or clinical service; the article explains official warning language without estimating an individual likelihood of harm or replacing medical advice.
The FDA safety communication dated June 10, 2026 concerns the nonprescription Alli 60 mg Drug Facts label. The updated message tells consumers with a history of kidney stones or kidney disease to ask a healthcare professional before use, and tells users experiencing possible stone or kidney-injury symptoms to stop Alli and consult a doctor. The announcement describes acute kidney injury as a rare adverse event, not an expected digestive effect.
The distinction matters to someone shopping for OTC orlistat: nonprescription availability does not mean that pre-existing renal problems can be ignored. The revised warning is relevant when reviewing the Alli product label or deciding whether self-directed OTC purchase is appropriate. FDA did not publish a reliable personal-risk calculator or a prediction for every patient.
Kidney stones are solid deposits that can form in the urinary system; calcium oxalate is one common stone composition. Oxalate nephropathy is a condition in which calcium oxalate crystals deposit within the kidneys and may impair kidney function. A person might have urinary discomfort from a stone without developing acute kidney injury, and abnormal kidney function can have many causes besides orlistat.
Because the symptoms can overlap and are not specific to a medicine, this page does not label back pain or swelling as a diagnosis. A clinician may need examination, urine testing, blood testing or imaging as appropriate. The useful pre-purchase question is whether a kidney history warrants professional review, not whether a list of symptoms can substitute for evaluation.
Orlistat inhibits gastrointestinal lipases and reduces absorption of some dietary fat. In susceptible situations, unabsorbed fatty acids can bind calcium in the intestine, leaving less calcium available to bind dietary oxalate. More free oxalate may then be absorbed and excreted in urine. This helps explain the concern about enteric hyperoxaluria and calcium oxalate deposits.
That mechanistic chain is biologically plausible but does not mean every user will form stones. Underlying disease, renal function and other circumstances affect risk. For the digestive mechanism itself, see how orlistat works. The kidney page focuses on the clinical warning rather than treating theoretical pathways as an individual prediction.
FDA lists several symptoms that can occur with stones or kidney injury. They need medical attention rather than an attempt to self-manage by changing the orlistat dose. A symptom may have another cause, but dismissing it because kidney complications are uncommon would be unsafe.
The table is an educational translation of the warning, not a triage score. People with severe pain, inability to urinate, marked deterioration or significant systemic illness should obtain urgent medical assessment. Someone taking Alli who develops the listed symptoms should stop taking it and seek professional guidance.
| Possible warning sign | Why medical review matters | Action |
|---|---|---|
| Back or groin pain | Can occur with a urinary stone or another condition | Stop Alli and seek medical advice |
| Painful urination or visible blood | May indicate a urinary problem that needs testing | Stop Alli and seek medical advice promptly |
| Swelling of feet or legs | May accompany impaired kidney function or other disorders | Stop Alli and seek medical advice promptly |
| Reduced urination | Possible sign of kidney injury or obstruction | Stop Alli and seek medical advice promptly; urgent if severe |
A past stone, reduced kidney function, known renal disease or other history relevant to urinary oxalate should be disclosed before choosing Alli. FDA specifically calls for professional consultation when there has ever been kidney disease or stones. A clinician can consider the medical history, other conditions and medicines rather than making a decision solely from the product’s OTC designation.
Questions worth raising include whether the existing condition changes suitability, what warning symptoms to recognize, and whether follow-up testing is appropriate. Do not interpret a previous kidney stone as automatic proof of oxalate nephropathy, and do not assume normal symptoms today rule out relevant risk.
The prescription Xenical (orlistat 120 mg) labeling already discusses reports of oxalate nephrolithiasis and oxalate nephropathy, sometimes associated with kidney impairment. The June 2026 development specifically updated the OTC Alli label, rather than introducing kidney concerns for the first time across all orlistat products.
An Rx product can involve clinician evaluation and continued follow-up, but prescription status does not eliminate adverse effects. Readers comparing products should use the Xenical brand overview or the prescription 120 mg guide for product identity, not interpret this warning as evidence that either strength is risk-free.
Oily stool, increased defecation and gas with discharge are characteristic gastrointestinal effects of orlistat’s lipase inhibition. Painful urination, blood in urine or a decrease in urine output are not ordinary signs that the medicine is blocking dietary fat. Treating those warning symptoms as expected digestive adjustment could delay appropriate evaluation.
The separate GI effects guide covers what occurs in the bowel and the practical limits of symptom interpretation. This kidney-focused page emphasizes that unusual urinary symptoms and new swelling deserve medical assessment, even if digestive effects are also present.
A complete medication review also covers contraindications, interactions, nutrient absorption and other medical conditions. Depending on the medicine and patient, a pharmacist may need to discuss thyroid therapy, anticoagulants or other interacting drugs. Kidney warning information alone is not a comprehensive safety clearance for buying orlistat.
The orlistat interactions reference covers co-medication questions. Avoid stopping an important existing medicine independently; a healthcare professional should assess whether orlistat is appropriate alongside the treatment regimen.
FDA describes acute kidney injury as a rare adverse effect in the OTC warning update. Spontaneous adverse-event reports and case descriptions do not provide a dependable denominator for calculating the chance that a particular person will be affected. This page therefore does not supply a percentage risk or compare two orlistat strengths using unverified frequency estimates.
Risk depends on clinical context, and absence of a precise incidence figure is not a reason to minimize serious symptoms. For interpretation of longer treatment periods and monitoring, see long-term safety considerations; this page stays focused on renal warning signals.
Before selecting OTC Alli or obtaining prescription-strength orlistat, check the current U.S. product label, disclose prior kidney issues and ask a pharmacist or clinician about any relevant symptoms or follow-up. A website promising “kidney safe” treatment for everyone or encouraging use despite warning symptoms should not be trusted.
The orlistat buying options page covers lawful access routes. It cannot replace medical assessment, and an affiliate referral is not evidence that an offer is safe for someone with kidney disease.
The June 10, 2026 FDA notice is a dated regulatory event and should remain identified as such. Future label revisions or new safety communications could change the precise wording. When maintaining this page, editors should periodically review the current Alli Drug Facts label, the prescription Xenical label and subsequent FDA safety communications.
OrliLab separates those authoritative source documents from its main page JSON. This article provides accessible explanations while the publisher’s separately maintained source layer should support the key renal-risk claims; the distinction also avoids presenting an old announcement as a real-time stock or product update.
Yes. On June 10, 2026, FDA announced changes to the OTC Alli label concerning rare kidney injury and kidney stones.
No. FDA describes acute kidney injury as a rare adverse effect. An individual likelihood cannot be calculated from this page.
Back or groin pain, painful urination, blood in urine, reduced urination, and swelling of the feet or legs are among FDA-listed warning signs.
FDA advises stopping OTC Alli and contacting a doctor if back or groin pain, painful urination, blood in urine, leg swelling or less frequent urination develops. Severe symptoms warrant urgent assessment.
The updated OTC warning says people who have ever had kidney stones or kidney disease should ask a healthcare professional before use.
Yes. Prescription Xenical labeling already describes oxalate kidney stones and oxalate-related kidney injury. The June 2026 FDA communication specifically updated the OTC Alli Drug Facts warning.
No. Back pain has many possible causes. A clinician must assess the symptoms and decide whether testing is needed.
Reduced intestinal fat absorption can alter calcium binding and allow greater intestinal oxalate absorption in susceptible circumstances.
No. Do not independently alter the dose as a preventive measure. If you have a history of kidney stones or kidney disease, ask a clinician before use; seek prompt care for warning symptoms.
No. OTC medicines have warnings and eligibility limits. Kidney concerns are one reason to review the current label and medical history.